#VisualAbstract: Adjuvant Dabrafenib plus Trametinib Improves Outcomes in Stage III Melanoma
Click here to read this study in NEJM. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced ...
Tag: advanced melanoma
#VisualAbstract: Neoadjuvant Nivolumab and Ipilimumab Improve Outcomes in Resectable Stage III Melanoma
Click here to read this study in NEJM. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced ...
Atezolizumab, Vemurafenib, and Cobimetinib in Melanoma With CNS Metastases
1. Intracranial objective response rate was 42% in the BRAF V600 mutation-positive cohort and 27% in the BRAFV600 wild-type cohort. ...
#StudyGraphics: Atezolizumab in combination with vemurafenib and cobimetinib improve progression-free survival in patients with BRAFV600-advanced melanoma
Click to read this study in The Lancet Oncology.
#VisualAbstract: Neoadjuvant–Adjuvant vs. Adjuvant-Only Pembrolizumab in Advanced Melanoma
1. Event-free survival at 2 years was longer in the neoadjuvant-adjuvant group vs the adjuvant-only group (72% vs 49%). 2. ...
#VisualAbstract: Adjuvant pembrolizumab improves distant metastasis-free survival in stage IIB-C melanoma
Click to read this study in The Lancet Oncology.
#VisualAbstract: Tumor-infiltrating lymphocyte therapy compared to ipilimumab in advanced melanoma
1 .Tumor-infiltrating lymphocytes therapy shows improvements in PFS when compared to ipilimumab 2. All patients with tumor-infiltrating lymphocytes therapy had ...
Tumor-infiltrating lymphocyte therapy compared to ipilimumab in advanced melanoma
1 .Tumor-infiltrating lymphocytes therapy shows improvements in PFS when compared to ipilimumab 2. All patients with tumor-infiltrating lymphocytes therapy had ...
Overall survival with triplet therapy in BRAF V600 mutation-positive advanced melanoma
1. OS in triplet combination therapy (atezolizumab, vemurafenib, and cobimetinib) while numerally better, was not statistically improved when compared to ...
First-line treatment with immune checkpoint inhibitor rather than BRAF and MEK leads to improved survival
1. Starting treatment with nivolumab/ipilimumab rather than dabrafenib/trametinib resulted in an improvement in 2-year overall survival (72% vs 52%) 2. ...
License Our Award-Winning Physician-Written Medical News and Visual Abstracts
2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.
